Estimations des analystes de Wall Street pour Elicio Therapeutics, Inc. (ELTX): objectif de cours de consensus, recommandations achat/conserver/vente et prévisions de revenus, BPA et EBITDA pour les prochains exercices.
Consensus des analystes
| Achat fort | 0 |
| Achat | 1 |
| Conserver | 2 |
| Vente | 0 |
| Vente forte | 0 |
| Analystes au total | 3 |
| Note moyenne (1-5) | 0.33 |
Surprises de Résultats Récentes
| Date | BPA Réel | BPA Estimé | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.52 | ||
| 2026-08-13 | $-0.43 | $-0.54 | +20.0% |
| 2026-05-11 | $-0.65 | $-0.49 | -32.7% |
| 2026-03-12 | $-0.49 | $-0.47 | -4.3% |
| 2025-11-13 | $-0.60 | $-0.62 | +3.2% |
| 2025-08-07 | $-0.66 | $-0.69 | +4.3% |
| 2025-05-13 | $-0.87 | $-0.67 | -29.9% |
| 2025-03-31 | $-1.02 | $-0.94 | -8.5% |
Ratios de valorisation
| Prix / Valeur comptable | 3.91 |
| EV / EBITDA | -0.90 |
| Rendement du dividende | 0.00% |
Compte de Résultat (10 ans)
| Année | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenus | $7.3M | $6.6M | $4.0M | $1.5M | $2.9M | $28.3M | 0 | 0 | 0 | 0 |
| Coût des Ventes | $3.7M | $3.2M | $380000 | $1.1M | $1.8M | $1.2M | $1.1M | $1.2M | $1.2M | $1.1M |
| Marge Brute | $3.6M | $3.4M | $3.6M | $351000 | $1.1M | $27.1M | -$1.1M | -$1.2M | -$1.2M | -$1.1M |
| R&D | 0 | $196008 | $9.2M | $29.8M | $38.9M | $48.6M | $17.0M | $22.7M | $33.7M | $24.9M |
| Frais Généraux | $4.0M | $3.6M | $8.8M | $9.2M | $17.5M | $17.8M | $5.6M | $11.9M | $11.3M | $12.8M |
| Charges Opérationnelles | $4.0M | $3.8M | $18.0M | $38.9M | $56.3M | $66.4M | $22.7M | $34.6M | $43.8M | $36.6M |
| Résultat Opérationnel | -$419220 | -$397800 | -$14.3M | -$38.6M | -$55.3M | -$39.3M | -$23.7M | -$35.7M | -$45.0M | -$37.7M |
| EBITDA | $2.0M | $62540 | -$14.3M | -$40.2M | -$70.6M | -$51.9M | -$23.6M | -$33.0M | -$50.3M | -$37.3M |
| Charges d'Intérêt | $307450 | $300432 | 0 | 0 | $8.8M | $876442 | $3.6M | $1.1M | $455000 | $1.1M |
| Résultat Avant Impôts | $1.2M | $1.7M | -$20.0M | -$40.7M | -$80.1M | -$54.6M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| Impôts | $201858 | $452778 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Résultat Net | $307303 | $632241 | -$20.0M | -$40.7M | -$80.1M | -$26.4M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| BPA | $50.21 | $103.31 | $-6.79 | $-1.50 | $-1.93 | $-19.32 | $-9.10 | $-6.96 | $-4.25 | $-2.58 |
| BPA Dilué | $50.21 | $103.31 | $-6.79 | $-1.50 | $-1.93 | $-19.32 | $-9.10 | $-6.96 | $-4.25 | $-2.58 |
| Actions en Circulation (Diluées) | $6120 | $6120 | $2.9M | $8.2M | $8.2M | $3.2M | $3.1M | $5.1M | $12.2M | $15.3M |
Prix
| Prix | $1.77 |
| Capitalisation | $34M |
| Bourse | NASDAQ |
| Pays | US |
Entreprises liées: ACTU · APLT · CRBP · CRDF · MIST · MOLN · NKTX
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de ELTX: Vue d'ensemble · Financiers · Valorisation · Statistiques · Technique · Actionnariat · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions